9995 Stock Overview
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$44.45|
|52 Week High||HK$145.50|
|52 Week Low||HK$25.05|
|1 Month Change||65.24%|
|3 Month Change||-15.58%|
|1 Year Change||-64.12%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-36.32%|
Recent News & Updates
RemeGen's (HKG:9995) Earnings Aren't As Good As They Appear
Even though RemeGen Co., Ltd. ( HKG:9995 ) posted strong earnings recently, the stock hasn't reacted in a large way. We...
|9995||HK Biotechs||HK Market|
Return vs Industry: 9995 underperformed the Hong Kong Biotechs industry which returned -53.7% over the past year.
Return vs Market: 9995 underperformed the Hong Kong Market which returned -23.3% over the past year.
|9995 Average Weekly Movement||13.9%|
|Biotechs Industry Average Movement||10.2%|
|Market Average Movement||7.0%|
|10% most volatile stocks in HK Market||13.8%|
|10% least volatile stocks in HK Market||3.3%|
Stable Share Price: 9995 is more volatile than 90% of Hong Kong stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: 9995's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren’s syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors, as well as lung and urothelial cancer; and RC108 that is in Phase 1 clinical trials to treat various solid tumors.
RemeGen Fundamentals Summary
|9995 fundamental statistics|
Is 9995 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|9995 income statement (TTM)|
|Cost of Revenue||CN¥163.40m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||0.32|
|Net Profit Margin||11.08%|
How did 9995 perform over the long term?See historical performance and comparison
Is 9995 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 9995?
Other financial metrics that can be useful for relative valuation.
|What is 9995's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 9995's PE Ratio compare to its peers?
|9995 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
Price-To-Earnings vs Peers: 9995 is expensive based on its Price-To-Earnings Ratio (117.5x) compared to the peer average (20.5x).
Price to Earnings Ratio vs Industry
How does 9995's PE Ratio compare vs other companies in the Biotechs Industry?
Price-To-Earnings vs Industry: 9995 is expensive based on its Price-To-Earnings Ratio (117.5x) compared to the Hong Kong Biotechs industry average (14.7x)
Price to Earnings Ratio vs Fair Ratio
What is 9995's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||117.5x|
|Fair PE Ratio||43.7x|
Price-To-Earnings vs Fair Ratio: 9995 is expensive based on its Price-To-Earnings Ratio (117.5x) compared to the estimated Fair Price-To-Earnings Ratio (43.7x).
Share Price vs Fair Value
What is the Fair Price of 9995 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 9995 (HK$44.45) is trading below our estimate of fair value (HK$141.36)
Significantly Below Fair Value: 9995 is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: 9995 is poor value based on its PEG Ratio (1.5x)
Discover undervalued companies
How is RemeGen forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 9995's forecast earnings growth (80.5% per year) is above the savings rate (1.5%).
Earnings vs Market: 9995's earnings (80.5% per year) are forecast to grow faster than the Hong Kong market (17% per year).
High Growth Earnings: 9995's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 9995's revenue (34.5% per year) is forecast to grow faster than the Hong Kong market (10.2% per year).
High Growth Revenue: 9995's revenue (34.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 9995 is forecast to be unprofitable in 3 years.
Discover growth companies
How has RemeGen performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 9995 has a high level of non-cash earnings.
Growing Profit Margin: 9995 became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: 9995 has become profitable over the past 5 years, growing earnings by 22.4% per year.
Accelerating Growth: 9995 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 9995 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (12.8%).
Return on Equity
High ROE: 9995's Return on Equity (3.1%) is considered low.
Discover strong past performing companies
How is RemeGen's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 9995's short term assets (CN¥4.4B) exceed its short term liabilities (CN¥586.7M).
Long Term Liabilities: 9995's short term assets (CN¥4.4B) exceed its long term liabilities (CN¥90.2M).
Debt to Equity History and Analysis
Debt Level: 9995 is debt free.
Reducing Debt: 9995 had no debt 5 years ago.
Debt Coverage: 9995 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 9995 has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is RemeGen current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 9995's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 9995's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 9995's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 9995's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 9995 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jianmin Fang (58 yo)
Dr. Jianmin Fang is Co-Founder at RemeGen Co., Ltd. She has been Director, Chief Executive Officer and Chief Scientific Officer of RemeGen Co., Ltd. since October 16, 2008, and redesignated as an Executive...
Experienced Management: 9995's management team is considered experienced (2.1 years average tenure).
Experienced Board: 9995's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.1%.
RemeGen Co., Ltd.'s employee growth, exchange listings and data sources
- Name: RemeGen Co., Ltd.
- Ticker: 9995
- Exchange: SEHK
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: HK$28.266b
- Shares outstanding: 539.20m
- Website: https://www.remegen.com
Number of Employees
- RemeGen Co., Ltd.
- 58 Middle Beijing Road
- Yantai Development Zone
- Shandong Province
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/25 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.